RxDoctor Payments Data

Valerie Royal

Family · Gary, INNPI 1346346665

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 47 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$618
  • Viiv Healthcare Company$259
  • Vanda Pharmaceuticals Inc.$58
  • Novo Nordisk$32
  • EMD Serono, Inc.$25
  • Lundbeck LLC$25
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$1,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,053 in reported general payments places this provider in the 65th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$138
Medicare patients
17
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine12$35,005
OzempicSemaglutide24$25,180
JardianceEmpagliflozin28$24,242
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,542
Incruse ElliptaUmeclidinium Bromide12$4,327
Humalog Mix 75-25Insulin Lispro Protamin/Lispro11$3,692
Humalog Kwikpen U-100Insulin Lispro13$3,103
Atorvastatin Calcium393$2,435
Albuterol Sulfate HfaAlbuterol Sulfate35$1,105
Amlodipine Besylate272$965
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$755
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$713
Metformin Hcl136$705
Metformin Hcl ErMetformin Hcl107$596
Benazepril-HydrochlorothiazideBenazepril/Hydrochlorothiazide20$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato$259$35,00512 claims
Novo NordiskOzempic$32$25,18024 claims
GSKIncruse Ellipta$20$4,32712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,392 family providers in Indiana.

Other family in Gary

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →